<DOC>
	<DOCNO>NCT01710592</DOCNO>
	<brief_summary>Whilst oxaliplatin docetaxel establish activity treatment advance gastro-oesophageal cancer , role , however , management disease remain unclear . Furthermore unclear whether disease optimally treat combination two three cytotoxic drug . This trial aim determine whether combination oxaliplatin weekly docetaxel warrant investigation formal phase III trial . The combination epirubicin , oxaliplatin capecitabine comparator arm evaluation . Primary Objective : Determine randomise study response rate docetaxel oxaliplatin ( ElTax ) comparable epirubicin , oxaliplatin capecitabine ( EOX ) warrant evaluation advance gastro-oesophageal cancer . Secondary Objective : To examine effect treatment time progression , progression free survival , overall survival , quality life , associate toxicity treatment .</brief_summary>
	<brief_title>A Phase II Trial Epirubicin , Oxaliplatin Capecitabine ( EOX ) Versus Docetaxel Oxaliplatin ( ElTax ) Treatment Advanced Gastro-oesophageal Cancer</brief_title>
	<detailed_description>This randomise two-arm parallel group phase II study . 140 patient recruited period 12 month , randomise receive either eight 3-weekly cycle Epirubicin , Oxaliplatin Capecitabine ( EOX ) six 4-weekly cycle Docetaxel Oxaliplatin ( EITax ) .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Unresectable metastatic , histologically confirm adenocarcinoma stomach , gastrooesophageal junction lower third oesophagus measurable disease CT scanning ( see RECIST Criteria , Appendix C protocol definition measureable disease ) . No previous treatment advance disease ( previous adjuvant/neoadjuvant treatment acceptable &gt; 12 month previously ) . Absence serious concomitant illness ( i.e . MI within previous 6 month ) , uncontrolled angina , uncontrolled hypertension , severe COPD ( &gt; 3 admission infective exacerbation past 12 month ) etc . ECOG performance status ≤ 2 . Age ≥ 18 . Life expectancy ≥ 3 month Adequate renal , hepatic bone marrow function Creatinine clearance ≥ 50 ml/min calculate use Cockcroft Gault formula ( see Appendix L ) . Liver function test : Bilirubin ≤ 1.0 x ULN , AST ≤ 1.5 x ULN , ALT ≤ 1.5 x ULN , Haemoglobin &gt; 10.0 g/dl , Absolute neutrophil count &gt; 1.5 x 109 /L , Platelet count &gt; 100 x109/L . •Before randomisation , write informed consent must give accord ICH/GCP , national/local regulation . Symptoms sign peripheral neuropathy . Patients known second third degree heart block . Previous concurrent malignancy , exception basal cell carcinoma skin insitu neoplasia uterine cervix . Known hypersensitivity taxanes , oxaliplatin , fluoropyrimidines . Pregnant nursing . Female childbearing potential , male partner female child bear potential take adequate contraceptive precaution . Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>